Veracyte (VCYT) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.

6 brokers have issued 1 year price objectives for Veracyte's stock. Their VCYT share price forecasts range from $22.00 to $35.00. On average, they predict the company's stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $23.73 at the start of the year. Since then, VCYT shares have increased by 8.9% and is now trading at $25.84.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our VCYT earnings forecast.

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The biotechnology company earned $82.40 million during the quarter, compared to the consensus estimate of $75.75 million. Veracyte had a negative trailing twelve-month return on equity of 2.83% and a negative net margin of 9.70%. The company's quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.20) earnings per share.

ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Invesco Dynamic Biotechnology & Genome ETF (PBE), ARK Innovation ETF (ARKK), ARK Next Generation Internation ETF (ARKW), ROBO Global Artificial Intelligence ETF (THNQ) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Veracyte issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $330.00 million-$340.00 million, compared to the consensus revenue estimate of $330.51 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.66%), Wellington Management Group LLP (9.87%), BlackRock Inc. (9.12%), State Street Corp (5.76%), Artisan Partners Limited Partnership (5.01%) and Sumitomo Mitsui Trust Holdings Inc. (4.57%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho, Muna Bhanji and Robert S Epstein.
View institutional ownership trends.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $25.84.

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.87 billion and generates $296.54 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

The company employs 761 workers across the globe.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.